NCT03207438View on ClinicalTrials.gov

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

1,790

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

October 31, 2019

Conditions
Depressive Disorder, Major
Interventions
DRUG

Quetiapine 50 MG Extended Release Oral Tablet

OD

DRUG

Quetiapine Fumarate XR 150-300 mg

Dose ranged from 150 to 300mg, XR preparation, OD

DRUG

Placebos

Placebo

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Saskatchewan

OTHER